A. Bogdanov, A. Bogdanov, V. Klimenko, N. Verlov, V. Moiseyenko
Advances in cancer treatment require continuous improvement and the search for new therapies. Methods for direct photogeneration of singlet oxygen in tissue using IR lasers may be an effective alternative to photodynamic tumor therapy. The physical limitation for the direct photogeneration of singlet oxygen in a biological medium is the low absorption cross section of molecular oxygen. To overcome this limitation, it is necessary to use infrared radiation with a high power density, which in a living system is limited by thermal effects. A promising direction in the development of this approach could be the use of pulsed laser irradiation. By solving the problem of direct photogeneration of cytotoxic concentrations of singlet oxygen in a biological environment, including tumor tissue, without simultaneous heating to biocritical temperatures, it is possible to develop new effective and safe methods for the treatment of malignant neoplasms. Key words: single oxygen, direct photogeneration, reactive oxygen species, cancer therapy, photobiomodulation.
{"title":"Direct photogeneration of singlet oxygen in biological medium for cancer therapy","authors":"A. Bogdanov, A. Bogdanov, V. Klimenko, N. Verlov, V. Moiseyenko","doi":"10.31917/2401039","DOIUrl":"https://doi.org/10.31917/2401039","url":null,"abstract":"Advances in cancer treatment require continuous improvement and the search for new therapies. Methods for direct photogeneration of singlet oxygen in tissue using IR lasers may be an effective alternative to photodynamic tumor therapy. The physical limitation for the direct photogeneration of singlet oxygen in a biological medium is the low absorption cross section of molecular oxygen. To overcome this limitation, it is necessary to use infrared radiation with a high power density, which in a living system is limited by thermal effects. A promising direction in the development of this approach could be the use of pulsed laser irradiation. By solving the problem of direct photogeneration of cytotoxic concentrations of singlet oxygen in a biological environment, including tumor tissue, without simultaneous heating to biocritical temperatures, it is possible to develop new effective and safe methods for the treatment of malignant neoplasms. Key words: single oxygen, direct photogeneration, reactive oxygen species, cancer therapy, photobiomodulation.","PeriodicalId":101072,"journal":{"name":"Reports of Practical Oncology","volume":"75 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83188815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Moskalenko, V. Lyadov, D. G. Ichshanov, M. Chernykh, I. Sagaydak, M. R. Garipov, V. Galkin
Results There were no severe radiation-induced morbidity in the SBRT group, only 9,5% of patients developed grade 1 toxicity. In the surgery group complication rate was 18%, 1 lethal outcome was noted. The median follow-up was 24.6 months in the radiotherapy group and 22.8 months in the surgery group (p>0,05). 2 year LC rates was 62% in the SBRT group and 80% in the surgery group (p=0,019), and the 2-year OS was69.5% in the SBRT group and 84.7% in the surgery group (p = 0,03). The median mean dose was 54 Gy. Dose ≥51 Gy, was s a significant factor of improved local control. Conclusion SBRT is a safe and effective method of providing local control of colorectal cancer liver oligometastases. High-dose SBRT in hypofractionation regimen in selected patients with colorectal liver oligometastaseses comparable in terms of local control with surgery. Further studies are required to individualize the indications for this treatment method and optimize its methodology. Key words: Stereotactic radiation therapy, colorectal cancer, oligometastatic liver disease, hepatic resection
{"title":"Stereotactic radiotherapy vs. surgery in the treatment of colorectal cancer liver oligometastases","authors":"A. Moskalenko, V. Lyadov, D. G. Ichshanov, M. Chernykh, I. Sagaydak, M. R. Garipov, V. Galkin","doi":"10.31917/2401048","DOIUrl":"https://doi.org/10.31917/2401048","url":null,"abstract":"Results There were no severe radiation-induced morbidity in the SBRT group, only 9,5% of patients developed grade 1 toxicity. In the surgery group complication rate was 18%, 1 lethal outcome was noted. The median follow-up was 24.6 months in the radiotherapy group and 22.8 months in the surgery group (p>0,05). 2 year LC rates was 62% in the SBRT group and 80% in the surgery group (p=0,019), and the 2-year OS was69.5% in the SBRT group and 84.7% in the surgery group (p = 0,03). The median mean dose was 54 Gy. Dose ≥51 Gy, was s a significant factor of improved local control. Conclusion SBRT is a safe and effective method of providing local control of colorectal cancer liver oligometastases. High-dose SBRT in hypofractionation regimen in selected patients with colorectal liver oligometastaseses comparable in terms of local control with surgery. Further studies are required to individualize the indications for this treatment method and optimize its methodology. Key words: Stereotactic radiation therapy, colorectal cancer, oligometastatic liver disease, hepatic resection","PeriodicalId":101072,"journal":{"name":"Reports of Practical Oncology","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79164554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This article is a literature review of the available data on the history of origin, mechanism of action, and the main currently available conjugate-linked monoclonal antibodies. The use of conjugate-linked monoclonal antibodies in the therapy of both solid and hematological malignancies is a promising direction of anti-tumor therapy.
{"title":"Antibody-drug conjugates","authors":"E. О. Stepanova, F. Moiseenko, V. Moiseyenko","doi":"10.31917/2401007","DOIUrl":"https://doi.org/10.31917/2401007","url":null,"abstract":"This article is a literature review of the available data on the history of origin, mechanism of action, and the main currently available conjugate-linked monoclonal antibodies. The use of conjugate-linked monoclonal antibodies in the therapy of both solid and hematological malignancies is a promising direction of anti-tumor therapy.","PeriodicalId":101072,"journal":{"name":"Reports of Practical Oncology","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90162352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Real-world evidence studies in oncology: a trend or a necessity?","authors":"А.А. Zhuravkov, F. Moiseenko, A. Kolbin, V. Moiseyenko","doi":"10.31917/2401059","DOIUrl":"https://doi.org/10.31917/2401059","url":null,"abstract":"Key words: real-world data, RWD, randomized clinical trial, oncology.","PeriodicalId":101072,"journal":{"name":"Reports of Practical Oncology","volume":"67 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77242817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Surgical oncology has undergone a number of tactical changes in the era of the development of drug therapy, but is still the only treatment that can cure most solid forms of cancer. Recently, surgical interventions are increasingly acquiring an individual approach to the patient. Surgical oncology is part of a multifaceted multidisciplinary team with a single philosophy in understanding the biology of tumor development, as well as the contribution of other disciplines to the treatment of cancer patients. Key words: surgical oncology, cytoreductive surgery, intraoperative chemotherapy.
{"title":"Oncologic surgery in the era of drug therapy","authors":"","doi":"10.31917/2401027","DOIUrl":"https://doi.org/10.31917/2401027","url":null,"abstract":"Surgical oncology has undergone a number of tactical changes in the era of the development of drug therapy, but is still the only treatment that can cure most solid forms of cancer. Recently, surgical interventions are increasingly acquiring an individual approach to the patient. Surgical oncology is part of a multifaceted multidisciplinary team with a single philosophy in understanding the biology of tumor development, as well as the contribution of other disciplines to the treatment of cancer patients. Key words: surgical oncology, cytoreductive surgery, intraoperative chemotherapy.","PeriodicalId":101072,"journal":{"name":"Reports of Practical Oncology","volume":"103 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88981198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Gerasimov, M. V. Serebryanskaya, M. Davydov, R. Akchurin, Y. Buziashvili, E. Golubev, E. Charchyan, D. V. Puzenko, P. Kononets
Results: the incidence of postoperative complications was 33,8% (22/65), mortality – 3,1% (2/65); with phased tactics, these figures were 31,7% (19/60) and 3,3% (2/60); after simultaneous operations – 60% (3/5) and 0%, respectively. When performing operations for lung cancer after preliminary myocardial revascularization, the incidence of postoperative myocardial infarction was 3,3% (2/63), with a fatal outcome of 1,6% (1/63). In the long term, the total 1-, 3- and 5-year survival rate of radically operated patients was: at stage I – 95,7%, 86,3%, 64,7%, with II – 82,6%, 62,4%, 49,9% and at III – 66,0%, 55,8% and 34,3%, respectively (p = 0,042). Conclusions: the implementation of prophylactic myocardial revascularization in patients with lung cancer with severe forms of concomitant coronary artery disease allows to expand the group of radically operated patients, to achieve satisfactory immediate and long-term treatment results. Key words: lung cancer, coronary artery disease, lobectomy, bilobectomy, pneumonectomy, coronary artery bypass surgery, coronary angioplasty
{"title":"SURGICAL RESULTS OF LUNG CANCER TREATMENT IT PATIENTS WITH CONCOMITANT CORONARY ARTERY DISEAS","authors":"S. Gerasimov, M. V. Serebryanskaya, M. Davydov, R. Akchurin, Y. Buziashvili, E. Golubev, E. Charchyan, D. V. Puzenko, P. Kononets","doi":"10.31917/2401080","DOIUrl":"https://doi.org/10.31917/2401080","url":null,"abstract":"Results: the incidence of postoperative complications was 33,8% (22/65), mortality – 3,1% (2/65); with phased tactics, these figures were 31,7% (19/60) and 3,3% (2/60); after simultaneous operations – 60% (3/5) and 0%, respectively. When performing operations for lung cancer after preliminary myocardial revascularization, the incidence of postoperative myocardial infarction was 3,3% (2/63), with a fatal outcome of 1,6% (1/63). In the long term, the total 1-, 3- and 5-year survival rate of radically operated patients was: at stage I – 95,7%, 86,3%, 64,7%, with II – 82,6%, 62,4%, 49,9% and at III – 66,0%, 55,8% and 34,3%, respectively (p = 0,042). Conclusions: the implementation of prophylactic myocardial revascularization in patients with lung cancer with severe forms of concomitant coronary artery disease allows to expand the group of radically operated patients, to achieve satisfactory immediate and long-term treatment results. Key words: lung cancer, coronary artery disease, lobectomy, bilobectomy, pneumonectomy, coronary artery bypass surgery, coronary angioplasty","PeriodicalId":101072,"journal":{"name":"Reports of Practical Oncology","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82353801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Adoptive therapy with tumor-infiltrating lymphocytes (TIL) has been studied since 1980s. Although some trials showed very high efficacy in melanoma and other tumors no enough data were available for approval of the method perhaps due to the cost, complexity and reproducibility limited to academic centers. Last year the results of prospective phase III trial comparing TIL therapy to standard immunotherapy for melanoma were reported which proved the efficacy and even superiority of the method. This paper reviews the principles of adoptive TIL therapy and the perspectives for further developement.
{"title":"Tumor-infiltrating lymphocytes – from theory to real practice","authors":"","doi":"10.31917/2401019","DOIUrl":"https://doi.org/10.31917/2401019","url":null,"abstract":"Adoptive therapy with tumor-infiltrating lymphocytes (TIL) has been studied since 1980s. Although some trials showed very high efficacy in melanoma and other tumors no enough data were available for approval of the method perhaps due to the cost, complexity and reproducibility limited to academic centers. Last year the results of prospective phase III trial comparing TIL therapy to standard immunotherapy for melanoma were reported which proved the efficacy and even superiority of the method. This paper reviews the principles of adoptive TIL therapy and the perspectives for further developement.","PeriodicalId":101072,"journal":{"name":"Reports of Practical Oncology","volume":"421 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78118422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In clinical practice, the cancer treatment is certainly resulted from the biology of tumor growth, the modern understanding of which is based on the theory of genetic changes. In this regard, the effective strategy is the research and target on trigger mutations in the tumor. Obviously, a malignant neoplasm is the set of the different populations of epithelial, stromal and immune cells as well as intercellular matrix with dynamically changing blood flow, nutrients, acid-base state and oxygen concentration, which is almost not taken into account by clinicians.
{"title":"Cancer evolution as a new target of treatment paradigm","authors":"V. Chubenko","doi":"10.31917/2401033","DOIUrl":"https://doi.org/10.31917/2401033","url":null,"abstract":"In clinical practice, the cancer treatment is certainly resulted from the biology of tumor growth, the modern understanding of which is based on the theory of genetic changes. In this regard, the effective strategy is the research and target on trigger mutations in the tumor. Obviously, a malignant neoplasm is the set of the different populations of epithelial, stromal and immune cells as well as intercellular matrix with dynamically changing blood flow, nutrients, acid-base state and oxygen concentration, which is almost not taken into account by clinicians.","PeriodicalId":101072,"journal":{"name":"Reports of Practical Oncology","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86734906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Liquid biopsy is the analysis of tumor fragments (entire cells, nucleic acids,proteins) in hysiological and pathological body liquids. This technology has already been included in standard procedures of detecting secondary mutations, which are associate with acquired drug resistance. Liquid biopsy is a promising tool for early cancer detection, evaluation of the success of radical cancer surgery, monitoring of residual tumor disease, assessment of treatment efficacy etc.
{"title":"LIQUID BIOPSY IN CLINICAL ONCOLOGY","authors":"E. Imyanitov, E. Kuligina, G. Januś","doi":"10.31917/2304211","DOIUrl":"https://doi.org/10.31917/2304211","url":null,"abstract":"Liquid biopsy is the analysis of tumor fragments (entire cells, nucleic acids,proteins) in hysiological and pathological body liquids. This technology has already been included in standard procedures of detecting secondary mutations, which are associate with acquired drug resistance. Liquid biopsy is a promising tool for early cancer detection, evaluation of the success of radical cancer surgery, monitoring of residual tumor disease, assessment of treatment efficacy etc.","PeriodicalId":101072,"journal":{"name":"Reports of Practical Oncology","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81469982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Digitalization, artificial intelligence and machine learning are increasingly being introduced into medicine and pathology in particular. The review presents the definitions and modern concepts of this field, the possibilities and limitations, the advantages and disadvantages of their use. Examples from representative publications are discussed.
{"title":"OPPORTUNITIES AND PROSPECTS OF ARTIFICIAL INTELLIGENCE IN THE PATHOLOGICAL IDENTIFICATION OF CANCER","authors":"K. Shelekhova","doi":"10.31917/2304234","DOIUrl":"https://doi.org/10.31917/2304234","url":null,"abstract":"Digitalization, artificial intelligence and machine learning are increasingly being introduced into medicine and pathology in particular. The review presents the definitions and modern concepts of this field, the possibilities and limitations, the advantages and disadvantages of their use. Examples from representative publications are discussed.","PeriodicalId":101072,"journal":{"name":"Reports of Practical Oncology","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88073078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：